Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.54 is 426% above its 1-year average of 0.10, near the high end of its 1-year range (-0.30–0.54).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.54.
DEBT TO EQUITY RATIO
0.54
DEBT TO EQUITY RATIO AVG TTM
N/A
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.15
median of 414 covered companies
CURRENT VS SECTOR MEDIAN
+272.87%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$408.21M
Debt to Equity Ratio
0.54
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.47M
Debt to Equity Ratio
0.12
TTM Avg
0.11
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$410.54M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$416.68M
Debt to Equity Ratio
0.13
TTM Avg
0.12
3Y Avg
0.17
5Y Avg
0.17
Market Cap
$428.16M
Debt to Equity Ratio
0.15
TTM Avg
1.54
3Y Avg
0.83
5Y Avg
0.58
Market Cap
$373.40M
Debt to Equity Ratio
0.40
TTM Avg
0.56
3Y Avg
1.08
5Y Avg
0.88
Market Cap
$447.43M
Debt to Equity Ratio
0.37
TTM Avg
0.04
3Y Avg
0.21
5Y Avg
0.20
Market Cap
$368.91M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.11
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $408.21M | 0.54 | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | 0.12 | 0.11 | 0.11 | 0.11 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Carlsmed, Inc. (CARL)vs › | $415.93M | 0.26 | 0.18 | 0.18 | 0.18 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | 0.13 | 0.12 | 0.17 | 0.17 |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | 0.15 | 1.54 | 0.83 | 0.58 |
| Canopy Growth Corporation (CGC)vs › | $373.40M | 0.40 | 0.56 | 1.08 | 0.88 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | 0.37 | 0.04 | 0.21 | 0.20 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | 0.00 | 0.00 | 0.00 | 0.11 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | 0.55 | 2.43 | 1.26 | 0.85 |
Debt/Equity
0.54
Current Ratio
9.89
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.54 |
| 2026-03-31 | 0.46 |
| 2025-12-31 | -0.29 |
| 2025-09-30 | -0.30 |
